ライフサイエンスコーパス: stem cell transplantation

1 who are potential candidates for autologous stem cell transplantation.

2 implications for HIV cure regimens based on stem cell transplantation.

3 ed into intensive strategies with autologous stem cell transplantation.

4 remission and allow subsequent hematopoietic stem cell transplantation.

5 be achievable with allogeneic hematopoietic stem cell transplantation.

6 isease in both solid organ and hematopoietic stem cell transplantation.

7 condition following allogeneic hematopoietic stem cell transplantation.

8 y triggered IBD and allogeneic hematopoietic stem cell transplantation.

9 n 1 year after treatment with haematopoietic stem cell transplantation.

10 olution to rapid relapse after hematopoietic stem cell transplantation.

11 27-321) days after allogeneic hematopoietic stem cell transplantation.

12 e permitted to come off study for autologous stem cell transplantation.

13 lications are common following hematopoietic stem cell transplantation.

14 ween whole-brain radiotherapy and autologous stem cell transplantation.

15 rtality in the first year after haemopoietic stem cell transplantation.

16 lete the HSC niche to optimize hematopoietic stem cell transplantation.

17 e development within 1 year of hematopoietic stem cell transplantation.

18 s (2.7%) undergoing autologous hematopoietic stem cell transplantation.

19 (SLET), a relatively new technique of limbal stem cell transplantation.

20 patients underwent allogeneic hematopoietic stem cell transplantation.

21 ay deserve intensive salvage with autologous stem cell transplantation.

22 nge, 10.5-124 d) in autologous hematopoietic stem cell transplantation.

23 erapy, and 71% had relapsed after autologous stem cell transplantation.

24 (95% CI 26.9-33.0) 1 year after haemopoietic stem cell transplantation.

25 ained from human recipients of hematopoietic stem cell transplantation.

26 cute lymphoblastic leukemia after allogeneic stem cell transplantation.

27 ertoire influenced the outcome of allogeneic stem cell transplantation.

28 a (HL) after failed hematopoietic autologous stem cell transplantation.

29 refractory to prior allogeneic hematopoietic stem cell transplantation.

30 D) is a severe complication of hematopoietic stem cell transplantation.

31 althy donor and patient after haploidentical stem cell transplantation.

32 olid organ transplantation and hematopoietic stem cell transplantation.

33 with multiple myeloma who are ineligible for stem cell transplantation.

34 d chemotherapy with or without hematopoietic stem cell transplantation.

35 ity and mortality from GVHD after allogeneic stem cell transplantation.

36 atently infected cells before haematopoietic stem cell transplantation.

37 icient alternative to improve the outcome of stem cell transplantation.

38 curative option for CMML remains allogeneic stem cell transplantation.

39 HD) is a major complication of hematopoietic stem cell transplantation.

40 plication for patients undergoing allogeneic stem cell transplantation.

41 target in patients undergoing hematopoietic stem cell transplantation.

42 Seven patients underwent hematopoietic stem cell transplantation.

43 itional late effects following hematopoietic stem cell transplantation.

44 or relapsed at </=12 months from autologous stem cell transplantation.

45 transfusion in the setting of hematopoietic stem-cell transplantation.

46 -versus-host disease (GVHD) after allogeneic stem-cell transplantation.

47 and pediatric patients undergoing allogeneic stem-cell transplantation.

48 be halted only with allogeneic hematopoietic stem-cell transplantation.

49 in each treatment group underwent allogeneic stem-cell transplantation.

50 ients who are eligible to receive autologous stem-cell transplantation.

51 in patients with acute GVHD after allogeneic stem-cell transplantation.

52 GVHD who had received consecutive allogeneic stem-cell transplantation.

53 rom last anti-lymphoma therapy, and previous stem-cell transplantation.

54 nt was treated with allogeneic hematopoietic stem-cell transplantation.

55 were ineligible for intensive chemotherpy or stem-cell transplantation.

56 deficit was fully corrected by hematopoietic stem-cell transplantation.

57 ess and death after allogeneic hematopoietic stem-cell transplantation.

58 ical outcomes after allogeneic hematopoietic stem-cell transplantation.

59 th cancer and those undergoing hematopoietic stem-cell transplantation.

60 and earlier relapse, respectively, received stem cell transplantations.

61 patients had previously received autologous stem cell transplantation, 101 (95%) were refractory to

62 y or to undergo observation after autologous stem-cell transplantation (120 patients per group); 59 p

63 d in 2,635 patients undergoing hematopoietic stem cell transplantation (5.0%).

64 s (91%), alkylating agents (91%), autologous stem cell transplantation (78%), thalidomide (44%), and

65 At 12 months following hematopoietic stem cell transplantation, 89 patients (66.9%) who devel

66 The success of allogeneic hematopoietic stem cell transplantation, a key treatment for many diso

67 as been achieved by allogeneic hematopoietic stem cell transplantation, a procedure hampered by high

68 During hematopoietic stem cell transplantation, a substantial number of donor

69 In hematopoietic stem cell transplantation, acute graft-versus-host-disea

70 aft-vs-host-disease (cGVHD) after allogeneic stem cell transplantation (AHSCT) may resemble autoimmun

71 ate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSCT), but can also damage h

72 isease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by suppressing conv

73 emia botulism in an allogeneic hematopoietic stem cell transplantation (allo-HCT) recipient.

74 essfully treated by allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in childhood.

75 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially c

76 een speculated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may cure this diso

77 on in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), who receive inten

78 and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

79 investigated during allogeneic hematopoietic stem cell transplantation (allo-HSCT).

80 nted case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several subsequent

81 pse mortality and morbidity after allogeneic stem cell transplantation (allo-SCT).

82 pse morbidity and mortality after allogeneic stem cell transplantation (allo-SCT).

83 overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT).

84 ause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT).

85 mia (GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is potent against ch

86 nge, 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 14.2 days (interquartile r

87 (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients (2.7%) undergo

88 ous complication of allogeneic hematopoietic stem cell transplantation and causes disabling systemic

89 Trials of hematopoietic stem cell transplantation and gene therapy for primary i

90 after definitive therapy with hematopoietic stem cell transplantation and gene therapy.

91 inferior platelet recovery after cord blood stem cell transplantation and may underlie inefficient p

92 y have relevance for clinical haematopoietic stem cell transplantation and mobilization protocols.

93 ocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors dir

94 mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contrib

95 's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin.

96 n's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin.

97 for pediatric patients undergoing autologous stem-cell transplantation and for adult and pediatric pa

98 homa who had failed to respond to autologous stem-cell transplantation and had either relapsed after

99 thdrawn from the study to undergo allogeneic stem-cell transplantation and later died from transplant

100 geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease

101 ain complication of allogeneic hematopoietic stem cell transplantation, and many efforts have been ma

102 cement therapy, oral lipid-lowering therapy, stem-cell transplantation, and liver transplantation.

103 ng choice of chemoimmunotherapy, the role of stem-cell transplantation, and mechanism-based targeted

104 Furthermore, we took a hematopoietic stem cell transplantation approach to generating a SCD m

105 ditional studies and referral for allogeneic stem cell transplantation are also discussed.

106 Donors for allogeneic stem cell transplantation are preferentially matched wit

107 be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit.

108 tion before high-dose therapy and autologous stem cell transplantation (ASCT) in patients with newly

109 lymphoma (DLBCL) not eligible for autologous stem cell transplantation (ASCT) or having relapse after

110 n and up-front consolidation with autologous stem cell transplantation (ASCT) remain controversial is

111 eauville score </=2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive pa

112 on, and patients could proceed to autologous stem cell transplantation (ASCT).

113 it of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment

114 sed multiple myeloma with salvage autologous stem-cell transplantation (ASCT) compared with oral cycl

115 idomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged

116 sized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at t

117 eGEV) as induction therapy before autologous stem-cell transplantation (ASCT) in patients with relaps

118 lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for pa

119 blative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to w

120 rkers that predict outcomes after autologous stem-cell transplantation (ASCT).

121 (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT).

122 rials, adult patients who undergo autologous stem-cell transplantation at experienced centers may rec

123 ts with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk o

124 gic malignancies who underwent hematopoietic stem cell transplantation, B-1 cells were found in the c

125 USA, who received an allogeneic haemopoietic stem cell transplantation between Jan 1, 2007, and Feb 2

126 with MM and underwent autologous bone marrow stem cell transplantation (BMT) were evaluated.

127 In a murine model of hematopoietic stem cell transplantation, CAR-modified Tregs were more

128 After hematopoietic stem cell transplantation, CD69(+)CXCR6(+) lymphoid tiss

129 Allogeneic hematopoietic stem cell transplantation combines cytoreductive chemoth

130 patients undergoing allogeneic hematopoietic stem cell transplantation continue to improve, but chron

131 Allogeneic stem cell transplantation corrected the immunologic defe

132 Previous studies have indicated that stem-cell transplantation could be an effective treatmen

133 melphalan (HDM) chemotherapy and autologous stem cell transplantation, depending on iFISH results.

134 enerates an adaptive immune memory response, stem cell transplantation disrupts this learned immunity

135 ry distress syndrome following hematopoietic stem cell transplantation do not meet criteria for a mor

136 treated early after allogeneic hematopoietic stem cell transplantation do not support the use of extr

137 requent complication following hematopoietic stem cell transplantation, dramatically influencing pati

138 n with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with

139 lications, donor selection for hematopoietic stem cell transplantation, evaluation of comorbidities,

140 logenous leukemia treated with hematopoietic stem cell transplantation, extended use of atovaquone fo

141 primary immunodeficiency disease registries, stem cell transplantation facilities, and neonatal scree

142 D (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cyc

143 xamethasone (RVD) with or without autologous stem-cell transplantation, followed by lenalidomide main

144 rwent additional chemotherapy and autologous stem cell transplantation for bone marrow rescue.

145 sfully treated with allogeneic hematopoietic stem cell transplantation for more than 4 decades.

146 cord blood provides access to hematopoietic stem cell transplantation for patients lacking matched b

147 Over the past years, stem cell transplantation for repair of the CNS has rece

148 stemic chemotherapy or subsequent autologous stem cell transplantation for treatment of hematological

149 following haplo-mismatched, T cell-depleted stem cell transplantations for the treatment of acute my

150 patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may inform prognostic

151 ukemia who received allogeneic hematopoietic stem cell transplantation from a homozygous CCR5 Delta32

152 ssion halted after allogeneic haematopoietic stem cell transplantation from a related donor.

153 HD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling.

154 To highlight the utility for hematopoietic stem cell transplantation, frozen samples of cord blood

155 ndrome and two who had received haemopoietic stem cell transplantation had either no response or were

156 e repertoires at 9-12 mo after hematopoietic stem cell transplantation had increased disease-free sur

157 8.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a l

158 a) therapy is inefficient, and hematopoietic stem cell transplantation has a poor prognosis.

159 Allogeneic haematopoietic stem cell transplantation has been demonstrated to provi

160 Allogeneic stem cell transplantation has the possibility for cure b

161 High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatmen

162 iatric patients undergoing sequential LT and stem cell transplantation have been described in the lit

163 rapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new

164 oma ineligible for intensive chemotherapy or stem-cell transplantation have longer progression-free s

165 isease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT [allo-HCT]).

166 the major cause of allogeneic hematopoietic stem cell transplantation (HCT) failure, and the prognos

167 ce: During hospitalization for hematopoietic stem cell transplantation (HCT), patients receive high-d

168 High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is supposed to over

169 (CMV) and undergoing allogeneic haemopoietic stem-cell transplantation (HCT) are at risk for CMV reac

170 gh-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) or nonmyeloablative

171 itor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed by either

172 A-TMA) occurs frequently after hematopoietic stem cell transplantation (HSCT) and can lead to signifi

173 virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT) and enteric graft-versu

174 Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal

175 t of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and to identify novel i

176 of stem cells to use in early haematopoietic stem cell transplantation (HSCT) approaches for several

177 nfections following allogeneic hematopoietic stem cell transplantation (HSCT) are a major cause of mo

178 gical complications (NC) after hematopoietic stem cell transplantation (HSCT) are rare events.

179 rly recognized complication of hematopoietic stem cell transplantation (HSCT) associated with excessi

180 Allogeneic hematopoietic stem cell transplantation (HSCT) can lead to donor-speci

181 ific T-cell immunity following hematopoietic stem cell transplantation (HSCT) could assist clinicians

182 Hematopoietic stem cell transplantation (HSCT) cures the T-lymphocyte,

183 ng has improved survival after hematopoietic stem cell transplantation (HSCT) for hemophagocytic lymp

184 HIV-infected person following hematopoietic stem cell transplantation (HSCT) from an allogeneic dono

185 Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-haploidenti

186 tive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not been prospectiv

187 recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic synd

188 provides a clear rationale for hematopoetic stem cell transplantation (HSCT) in patients with severe

189 Allogeneic hematopoietic stem cell transplantation (HSCT) is a critically importa

190 Myeloablative autologous hematopoietic stem cell transplantation (HSCT) is a mainstay of therap

191 Hematopoietic stem cell transplantation (HSCT) is an important therapy

192 Autologous hematopoietic stem cell transplantation (HSCT) is increasingly conside

193 Autologous hematopoietic stem cell transplantation (HSCT) is increasingly used fo

194 Allogeneic hematopoietic stem cell transplantation (HSCT) is used as a therapeuti

195 Autologous hematopoietic stem cell transplantation (HSCT) of gene-modified cells

196 Hematopoietic stem cell transplantation (HSCT) offers curative therapy

197 Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only treatm

198 Hematopoietic stem cell transplantation (HSCT) represents a potential

199 une tolerance after allogeneic hematopoietic stem cell transplantation (HSCT) requires the balanced r

200 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monitored.

201 verall survival and outcome of hematopoietic stem cell transplantation (HSCT) were not influenced by

202 revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing safe infusion

203 use of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiolo

204 ve chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least in younger pa

205 ing complication of allogeneic hematopoietic stem cell transplantation (HSCT), posing as a significan

206 ces in the field of allogeneic hematopoietic stem cell transplantation (HSCT), viral infections are s

207 tment failure after allogeneic hematopoietic stem cell transplantation (HSCT).

208 derwent a sequential liver and hematopoietic stem cell transplantation (HSCT).

209 burden in patients undergoing hematopoietic stem cell transplantation (HSCT).

210 gested favorable outcome after hematopoietic stem cell transplantation (HSCT).

211 nstitution postirradiation and hematopoietic stem cell transplantation (HSCT).

212 fe-threatening complication of hematopoietic stem cell transplantation (HSCT).

213 complications after allogeneic hematopoietic stem cell transplantation (HSCT).

214 alan-based chemotherapy before hematopoietic stem cell transplantation (HSCT).

215 f the main complications after hematopoietic stem cell transplantation (HSCT).

216 (CGD) can be cured by allogeneic hemopoietic stem cell transplantation (HSCT).

217 ncy can be cured by allogeneic hematopoietic stem cell transplantation (HSCT).

218 eficiencies (PIDs) who require hematopoietic stem cell transplantation (HSCT).

219 and mortality after allogeneic hematopoietic stem cell transplantation (HSCT).

220 s a complication of allogeneic hematopoietic stem cell transplantation (HSCT).

221 ate complication of allogeneic hematopoietic stem cell transplantation (HSCT).

222 l population, especially after hematopoietic stem cell transplantation (HSCT).

223 y in patients after allogeneic hematopoietic stem cell transplantation (HSCT).

224 f mobilisation and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisat

225 Haemopoietic stem-cell transplantation (HSCT) eradicates host haemopo

226 nces the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclear.

227 umor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hema

228 tients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to

229 major limitation of allogeneic haemopoietic stem-cell transplantation (HSCT), for which no approved

230 after treatment and subsequent haemopoietic stem-cell transplantation (HSCT).

231 Autologous stem cell transplantation improved the outcomes of patie

232 pired by this case, we studied the impact of stem cell transplantation in a macaque simian/HIV (SHIV)

233 logical benefit of allogeneic haematopoietic stem cell transplantation in adult cerebral adrenoleukod

234 The role of hematopoietic stem cell transplantation in indolent lymphoma has been

235 with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS l

236 ays a key role post allogeneic hematopoietic stem cell transplantation in the generation of a broad b

237 safe and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cereb

238 Specific complications during stem cell transplantation included deterioration of moto

239 (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (six of 11) of

240 rtality in the first year after haemopoietic stem cell transplantation, independent of the use of pre

241 only be cured when allogeneic hematopoietic stem-cell transplantation induces a graft-versus-leukemi

242 Hematopoietic stem cell transplantation is a potential curative therap

243 Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-v

244 ely affected patients for whom hematopoietic stem cell transplantation is not available.

245 Hematopoietic stem cell transplantation is the current standard of car

246 Hematopoietic stem cell transplantation is the standard treatment; how

247 Stem cell transplantation is used to treat these disease

248 Allogeneic haemopoietic stem-cell transplantation is the only existing cure but

249 hyrin in the liver, LT without hematopoietic stem cell transplantation leaves the new liver at risk f

250 These results suggest that BM stem cell transplantation may be a promising therapy for

251 onse, a consolidation by means of autologous stem cell transplantation may offer a greater chance of

252 lation followed by autologous haematopoietic stem cell transplantation, mesenchymal and related stem

253 transfusions and hydroxycarbamide, although stem cell transplantation might be a potentially curativ

254 lleagues asked whether the results of neural stem cell transplantation might be improved by accommoda

255 al spheroids and suggest that haematopoietic stem cell transplantation might have a therapeutic role

256 nts, etoposide, and allogeneic hematopoietic stem cell transplantation; more than 50% of children who

257 Despite normal numbers of hematopoietic stem cells, transplantation of Fubp1(-/-) hematopoietic

258 Autologous stem cell transplantation offers a safe treatment platfo

259 rophy treated with allogeneic haematopoietic stem cell transplantation on a compassionate basis in fo

260 Hematopoietic stem cell transplantation or gene therapy offer a cure,

261 ays of 30 primary samples from hematopoietic stem cell transplantation patients with and without cGVH

262 al immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses.

263 ose chemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT) at Indiana University

264 ell transplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of

265 re than one lysosomal disorder (haemopoietic stem cell transplantation, pharmacological chaperones, s

266 sure to HDAC inhibitors; previous allogeneic stem-cell transplantation; previous autologous stem-cell

267 contrary, long-term allogeneic hematopoietic stem cell transplantation recipients otherwise eligible

268 All allogeneic hematopoietic stem cell transplantation recipients treated with venove

269 treatment of adult allogeneic hematopoietic stem cell transplantation recipients with grades III to

270 ot been assessed in allogeneic hematopoietic stem cell transplantation recipients.

271 N) in children with cancer and hematopoietic stem-cell transplantation recipients.

272 e response, rate of allogeneic hematopoietic stem-cell transplantation, relapse-free survival, overal

273 -SIGN (rs11465384 and rs7248637), allogeneic stem cell transplantation, respiratory virus infection,

274 ogical immune responses following allogeneic stem cell transplantation resulting in acute graft-versu

275 oring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis.

276 Allogeneic stem cell transplantation (SCT) has been proposed as a t

277 r censoring patients who received allogeneic stem cell transplantation (SCT) in first remission at SC

278 Admission of allogeneic stem cell transplantation (SCT) recipients to the intens

279 ) in patients (n = 80) undergoing allogeneic stem cell transplantation (SCT), using the composite end

280 time points, and did not undergo allogeneic stem cell transplantation (SCT).

281 ion is a major complication after allogeneic stem cell transplantation (SCT).

282 ssion and no identified donor for allogeneic stem-cell transplantation (SCT) were eligible.

283 Therefore, allogeneic hematopoietic stem cell transplantation should always be an initial co

284 ents with chemosensitive disease, autologous stem cell transplantation should be considered at first

285 -host disease after allogeneic hematopoietic stem cell transplantation, suggesting normal suppressive

286 thin 240 days after allogeneic hematopoietic stem cell transplantation survived compared to six of 13

287 donor selection in allogeneic hematopoietic stem cell transplantation, the molecular determinant of

288 mproved KIR-HLA mismatching in hematopoietic stem cell transplantation therapy for leukemia and new,

289 ression in Noonan syndrome and for improving stem cell transplantation therapy in Noonan-syndrome-ass

290 Chimera formation, generated by stem cell transplantation to the embryo, is a stringent

291 children shortly before and after allogeneic stem cell transplantation twice weekly by use of a comme

292 e NKG2D signaling in unrelated hematopoietic stem cell transplantation (uHSCT).

293 atient outcomes and optimal treatment (early stem cell transplantation vs long-term administration of

294 Until recently, hematopoietic stem cell transplantation was the only curative option f

295 nificance after HLA 10/10 matched allogeneic stem cell transplantation, we show that in this matched

296 pediatric cancer or undergoing hematopoietic stem cell transplantation when used as screening tools d

297 complication after allogeneic hematopoietic stem cell transplantation which causes high morbidity an

298 ease and was reduced following hematopoietic stem cell transplantation, which is the only therapy cur

299 VHD) is a serious complication of allogeneic stem cell transplantation with few effective options ava

300 em-cell transplantation; previous autologous stem-cell transplantation within 12 weeks of baseline; a